Myung In Pharmaceutical LTD. (KRX:317450)

KRX:317450 Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	280,618	269,435	242,338	225,828	209,250	187,837
Other Revenue	-0	-	-	-0	-0	-
Revenue	280,618	269,435	242,338	225,828	209,250	187,837
Revenue Growth (YoY)	24.26%	11.18%	7.31%	7.92%	11.40%	3.33%
Cost of Revenue	110,300	100,556	88,413	82,280	70,954	66,226
Gross Profit	170,317	168,879	153,925	143,549	138,297	121,611
Selling, General & Admin	68,842	67,800	62,249	57,227	57,643	53,001
Research & Development	4,133	3,684	4,037	4,749	2,448	2,651
Other Operating Expenses	1,674	1,588	1,485	3,564	1,326	1,236
Operating Expenses	78,360	76,124	70,306	67,646	64,091	56,678
Operating Income	91,958	92,754	83,618	75,903	74,206	64,933
Interest Expense	-286.68	-322.65	-333.54	-106.64	-133.33	-47.92
Interest & Investment Income	9,215	8,621	6,218	2,916	835.94	278.98
Currency Exchange Gain (Loss)	6,641	5,490	1,204	2,687	4,063	-2,932
Other Non Operating Income (Expenses)	35.21	-9,548	527.79	406.58	797.02	904.06
EBT Excluding Unusual Items	107,562	96,994	91,235	81,806	79,768	63,136
Gain (Loss) on Sale of Investments	-8,310	-8,310	826.42	-	-	-
Gain (Loss) on Sale of Assets	-703.18	-609.54	-0.32	10.7	6.39	-3,584
Pretax Income	98,549	88,075	92,061	81,817	79,775	59,552
Income Tax Expense	20,633	19,404	17,550	24,383	20,024	14,074
Net Income	77,916	68,671	74,512	57,434	59,750	45,478
Net Income to Common	77,916	68,671	74,512	57,434	59,750	45,478
Net Income Growth	35.66%	-7.84%	29.73%	-3.88%	31.38%	6.07%
Shares Outstanding (Basic)	11	11	11	11	11	11
Shares Outstanding (Diluted)	11	11	11	11	11	11
EPS (Basic)	6956.75	6131.31	6652.82	5128.04	5334.82	4060.55
EPS (Diluted)	6956.75	6131.31	6652.82	5128.04	5334.82	4060.55
EPS Growth	35.66%	-7.84%	29.73%	-3.88%	31.38%	6.07%
Free Cash Flow	75,072	72,783	71,428	57,643	63,407	45,488
Free Cash Flow Per Share	6702.89	6498.51	6377.48	5146.68	5661.37	4061.46
Dividend Per Share	500.000	500.000	2000.000	1000.000	1250.000	1750.000
Dividend Growth	-50.00%	-75.00%	100.00%	-20.00%	-28.57%	-
Gross Margin	60.69%	62.68%	63.52%	63.57%	66.09%	64.74%
Operating Margin	32.77%	34.43%	34.51%	33.61%	35.46%	34.57%
Profit Margin	27.77%	25.49%	30.75%	25.43%	28.55%	24.21%
Free Cash Flow Margin	26.75%	27.01%	29.47%	25.52%	30.30%	24.22%
EBITDA	104,549	105,217	95,058	87,238	85,824	75,894
EBITDA Margin	37.26%	39.05%	39.23%	38.63%	41.02%	40.40%
D&A For EBITDA	12,592	12,463	11,440	11,336	11,619	10,961
EBIT	91,958	92,754	83,618	75,903	74,206	64,933
EBIT Margin	32.77%	34.43%	34.51%	33.61%	35.46%	34.57%
Effective Tax Rate	20.94%	22.03%	19.06%	29.80%	25.10%	23.63%
Advertising Expenses	-	31,186	27,861	25,260	27,110	24,934

Source: S&P Global Market Intelligence. Standard template. Financial Sources.